Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2016 Jan;36(1):189–197. doi: 10.1161/ATVBAHA.115.306777

Figure 3.

Figure 3

Inhibition of platelet aggregation (IPA) in the 1 mg/kg PZ-128 dose cohort to 8, 12, and 20 μmol/L protease-activated receptor-1 agonist peptide, SFLLRN. Ex vivo aggregation was conducted in platelet-rich plasma by light transmission aggregometry and maximal and final (at 6 minutes) aggregation (mean±SD) normalized to baseline (t=0) for each agonist for (A) all subjects, and the subset receiving (B) aspirin (acetylsalicylic acid [ASA]).